Drugs / HER2-DC1
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03387553 | Jun 2018 → Aug 2023 | HER2 positive breast carcinoma, female breast carcinoma, invasive breast carcinoma, male breast carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HER2-DC1 | “Type 1 dendritic cell vaccines targeting HER2 (HER2-DC1) reinvigorates antitumor immunity” PMID 40097486 ↗ Mar 2025 |
| Known as | DC1 | “The study drug for this trial is DC1 study vaccine which is a HER2-sensitized dendritic cell (DC) study vaccine.” NCT03387553 ↗ |
| Modality | Vaccine | “Type 1 dendritic cell vaccines targeting HER2 (HER2-DC1) reinvigorates antitumor immunity” PMID 40097486 ↗ Mar 2025 |
| Route | Other | “given for 3 weeks prior to chemotherapy intranodal (IN) 1x/week (Arm A), IN 2x/week (Arm B), and 2x/week alternating intratumoral (IT) and IN (Arm C)” PMID 40097486 ↗ Mar 2025 |